#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14190	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2386	729.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1896	1896	T	997	T,G,A,C	991,2,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14190	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2386	729.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1630	1630	C	908	C,A	906,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24586	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3781	800.0	0	.	n	.	0	T695C	SNP	695	695	T	1153	1153	C	935	C,G	934,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24586	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3781	800.0	0	.	n	.	0	A1638G	SNP	1638	1638	A	2096	2096	G	849	G,T,A	844,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24586	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3781	800.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2429	2429	C	881	C,T,A,G	874,3,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24586	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3781	800.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2503	2503	A	834	A,G	833,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24586	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3781	800.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3055	3055	C	908	C,T,A	906,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	2160	folP	852	852	100.0	folP.l15.c4.ctg.1	1914	140.5	1	SNP	p	R228S	0	.	.	682	684	CGC	1269	1271	CGC	215;215;217	C;G,A;C	215;214,1;217	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5268	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3859	170.2	1	SNP	p	S91F	0	.	.	271	273	TCC	797	799	TCC	219;220;218	T,G;C,A;C	218,1;219,1;218	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5268	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3859	170.2	1	SNP	p	D95G	0	.	.	283	285	GAC	809	811	GAC	218;218;218	G;A,C;C,T	218;217,1;217,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5268	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3859	170.2	1	SNP	p	D95N	0	.	.	283	285	GAC	809	811	GAC	218;218;218	G;A,C;C,T	218;217,1;217,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1968	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1585	153.9	1	SNP	p	G45D	1	.	.	133	135	GAC	625	627	GAC	233;232;234	G,C;A,T;C	232,1;231,1;234	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1050	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1482	88.1	0	.	n	.	0	T10C	SNP	10	10	T	595	595	C	180	C	180	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1050	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c4.ctg.1	1482	88.1	0	.	n	.	0	A197.	DEL	197	197	A	781	781	A	209	A	209	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1844	1846	GCA	247;250;252	G;C;A	247;250;252	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2327	2329	ATT	247;243;243	A,C;T;T,C,G	246,1;243;240,2,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	1	SNP	p	D86N	0	.	.	256	258	GAC	797	799	GAC	206;210;210	G;A;C,A	206;210;209,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	1	SNP	p	S87R	0	.	.	259	261	AGT	800	802	AGT	209;212;214	A,G;G;T	208,1;212;214	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	1	SNP	p	S87I	0	.	.	259	261	AGT	800	802	AGT	209;212;214	A,G;G;T	208,1;212;214	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	1	SNP	p	S87W	0	.	.	259	261	AGT	800	802	AGT	209;212;214	A,G;G;T	208,1;212;214	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4776	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3506	169.7	1	SNP	p	S88P	0	.	.	262	264	TCC	803	805	TCC	213;215;215	T;C;C,T	213;215;214,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4484	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3143	177.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1762	1764	GGC	247;248;247	G;G,A,T;C,T	247;244,1,2;246,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1511	1513	GCA	232;231;232	G;C,A;A	232;230,1;232	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1514	1516	ATC	230;230;231	A;T;C,A	230;230;230,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1526	1528	GTG	242;243;245	G;T,G;G	242;242,1;245	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1526	1528	GTG	242;243;245	G;T,G;G	242;242,1;245	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2030	2032	ACC	231;230;231	A;C,T,A;C	230;227,1,1;230	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2084	2086	GCG	223;224;223	G;C,G;G,T	223;223,1;222,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2084	2086	GCG	223;224;223	G;C,G;G,T	223;223,1;222,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2207	2209	GGT	230;229;230	G;G;T	230;229;230	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2216	2218	GGC	234;235;233	G;G,A,T;C	234;233,1,1;233	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4130	penA	1752	1752	100.0	penA.l6.c4.ctg.1	3013	170.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2234	2236	CCG	229;230;230	C,T,G;C;G,C	227,1,1;230;229,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5382	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3547	189.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1765	1767	CCG	216;216;214	C,T;C;G	214,1;215;213	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2716	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2285	148.1	0	.	p	.	0	S22G	NONSYN	64	66	AGC	623	625	GGC	180;179;180	G,T;G;C,A	179,1;179;179,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2716	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2285	148.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	805	805	C	186	C	186	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	743	745	AAT	5;5;5	A;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	746	748	AAT	5;5;5	A;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	A222V	NONSYN	664	666	GCT	758	760	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	770	772	GCG	2;3;3	G;C;G	2;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	793	795	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	N237K	NONSYN	709	711	AAC	802	804	AAG	4;4;4	A;A;G	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	286	porB1a	984	292	90.2	porB1a.l15.c30.ctg.1	1010	26.3	0	.	p	.	0	D238fs	FSHIFT	712	712	G	805	805	G	4	G	4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2950	porB1b	1047	1047	99.9	porB1b.l6.c17.ctg.1	2027	181.2	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1204	1206	GGT	257;254;249	G;G,C;T	256;252,1;248	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2950	porB1b	1047	1047	99.9	porB1b.l6.c17.ctg.1	2027	181.2	1	SNP	p	G120K	0	.	.	358	360	GGC	913	915	GGC	254;256;256	G,A;G,T;C,T	253,1;255,1;255,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2950	porB1b	1047	1047	99.9	porB1b.l6.c17.ctg.1	2027	181.2	1	SNP	p	D121N	0	.	.	361	363	GAC	916	918	GAC	260;263;263	G;A;C,G	260;263;262,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2950	porB1b	1047	1047	99.9	porB1b.l6.c17.ctg.1	2027	181.2	1	SNP	p	A121D	1	.	.	361	363	GAC	916	918	GAC	260;263;263	G;A;C,G	260;263;262,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9730	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5325	227.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2217	2219	CAT	282;280;280	C;A;T	282;280;280	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1464	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1480	122.8	1	SNP	p	V57M	1	.	.	169	171	ATG	821	823	ATG	257;255;256	A;T;G,C,A	256;255;253,1,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
